HomeAI · summaries
Storia in 9 fonti
Samsung Biologics to Buy PolyPeptide in $1.8 Billion Deal
(Bloomberg) -- Samsung Biologics Co. agreed to acquire Switzerland’s PolyPeptide Group AG in an all-cash deal that values the contract drugmaker’s equity at about 1.46 billion Swiss francs ($1.8 billion), expanding its manufacturing capabilities.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
swissinfo.ch
Samsung Biologics to Buy PolyPeptide in $1.8 Billion Deal
(Bloomberg) -- Samsung Biologics Co. agreed to acquire Switzerland’s PolyPeptide Group AG in an all-cash deal that values the contract drugmaker’s equity at about 1.46 billion…
- ·
cnbc.com
Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal
South Korea's Samsung Biologics said on Monday that it had made an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) for Switzerland's PolyPeptide Group.
- ·
koreatimes.co.kr
Samsung Biologics to acquire PolyPeptide for $1.8 bil. - The Korea Times
Samsung Biologics said Monday it will acquire Swiss peptide drug manufacturer PolyPeptide Group through an all-cash public tender offer valued at a...
- ·
koreaherald.com
Samsung Biologics expands into peptides with $1.8b PolyPeptide deal
Samsung Biologics said Monday it has launched a $1.8 billion all-cash bid to acquire 100 percent of PolyPeptide, entering the peptide sector to bolster its mult
- ·
milanofinanza.it
Samsung Biologics, opa da 1,8 miliardi sulla svizzera PolyPeptide: focus sui farmaci dimagranti | MilanoFinanza News
La controllata del gruppo Samsung lancia un'opa da 1,46 miliardi di franchi svizzeri (1,8 miliardi di dollari) su PolyPeptide per rafforzarsi nei farmaci peptidici, trainati dalla…
- ·
rsi.ch
Offerta miliardaria per l’elvetica PolyPeptide - RSI
Samsung Biologics offre 1,5 miliardi di franchi per acquisire PolyPeptide, produttore svizzero di peptidi. Il CdA elvetico sostiene l'offerta.
- ·
Korean firm bids CHF1.5bn for Swiss pharma supplier Polypeptide
South Korean biopharmaceutical Samsung Biologics bids for Swiss pharma ingredient firm Polypeptide.
- ·
forbes.it
Samsung Biologics punta al mercato dei farmaci anti-obesità: opa da 1,8 miliardi sulla svizzera PolyPeptide
Samsung Biologics lancia un'opa da 1,8 miliardi di dollari su PolyPeptide. Il colosso sudcoreano punta sulle terapie peptidiche
- ·
fiercepharma.com
Samsung Biologics spreads wings with proposed $1.8B acquisition of Swiss CDMO PolyPeptide
South Korean contract manufacturer Samsung Biologics hopes to tap into the booming peptide production and weight loss market with plans to buy out Switzerland-based CDMO…
- ·
endpoints.news
Samsung Bio to expand its wheelhouse in $1.8B buy for peptide API maker
Samsung Biologics offers $1.8B for Swiss CDMO PolyPeptide, expanding beyond biologics into peptide APIs and the booming GLP-1 manufacturing market.